We anticipate that glioma tissues with relatively more MBD3 would respond better to therapeutic vaccination and immune-checkpoint-blockade agents (e.g., PD-1/PD-1L inhibitors and CTLA-4 blockade). This evidence concerns the gene CTLA4 and glioma.